NASDAQ: PDSBPds Biotechnology Corp Stock
$1.08+0.04 (+3.85%)
Updated Apr 17, 2025
PDSB Price
$1.08
Fair Value Price
N/A
Market Cap
$49.03M
52 Week Low
$0.85
52 Week High
$4.42
P/E
-1.05x
P/B
2.58x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$37.61M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
1.39
Operating Cash Flow
-$35M
Beta
1.87
Next Earnings
May 13, 2025
Ex-Dividend
N/A
Next Dividend
N/A
PDSB Overview
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma. In addition, it is developing PDS0201 for treating tuberculosis; PDS0202, an influenza vaccine candidate; and PDS0203, a vaccine for the prevention of COVID-19. The company has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine PDSB's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
PDSB
Ranked#231 of 463
Ranked#231 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.61 | A | |
| $7.75 | A | |
| $16.85 | A |
Be the first to know about important PDSB news, forecast changes, insider trades & much more!
PDSB News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PDSB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PDSB is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
PDSB is good value based on its book value relative to its share price (2.58x), compared to the US Biotechnology industry average (4.05x)
P/B vs Industry Valuation
PDSB is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more PDSB due diligence checks available for Premium users.
Valuation
PDSB fair value
Fair Value of PDSB stock based on Discounted Cash Flow (DCF)
Price
$1.08
Fair Value
$1.06
Overvalued by
2.20%
PDSB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
PDSB price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.05x
Industry
-177.72x
Market
27.98x
PDSB price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.58x
Industry
4.05x
PDSB is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PDSB's financial health
Profit margin
Revenue
$0.0
Net Income
-$8.0M
Profit Margin
0%
PDSB's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$45.4M
Liabilities
$26.4M
Debt to equity
1.39
PDSB's short-term assets ($45.05M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PDSB's short-term assets ($45.05M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PDSB's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
PDSB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$8.2M
Investing
$0.0
Financing
$172.8k
PDSB's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PDSB vs Biotech Stocks
Pds Biotechnology Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.